ERBB2 and non-small cell lung carcinoma: Dacomitinib, a second-generation EGFR-TKI/HER2-TKI, was already approved in the United States, Japan and the European Commission for first-line monotherapy treatment in patients with EGFR mutation-positive inoperable or recurrent NSCLC, which may be a powerful new treatment option compared with gefitinib (28, 29).